| Active substance | asciminib |
| Holder | Novartis |
| Status | Running |
| Indication | Patients with chronic myeloid leukemia (CML) in chronic phase previously treated with ≥ 2 TKIs |
| Public documents | Approbation |
| Approbation amendment | |
| Information for the patient | |
| Informed consent | |
| Last update |
28/11/2024 |